{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mahil SK"],"funding":["Psoriasis Association","Medical Research Council","National Institute for Health Research (NIHR)","NIHR Manchester Biomedical Research Centre","Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London"],"pagination":["80-90"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9214088"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["185(1)"],"pubmed_abstract":["<h4>Background</h4>Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments.<h4>Objectives</h4>We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation.<h4>Methods</h4>Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical "],"journal":["The British journal of dermatology"],"pubmed_title":["Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey."],"pmcid":["PMC9214088"],"funding_grant_id":["PsoProtect","NF-SI-0512-10105","NF-SI-0617-10075","MR/T02383X/1","MR/S003126/1"],"pubmed_authors":["Langan SM","Yates M","Torres T","Puig L","Smith CH","Yiu ZZN","Lambert J","Coker B","Moorhead L","Dand N","Capon F","Vesty A","De La Cruz C","Kelly J","Contreras CR","Marzo-Ortega H","Hyrich K","McAteer H","Sengupta R","Bruce IN","Mason KJ","Brown MA","Naldi L","Spuls P","Barker JN","Mahil SK","McInnes I","Cope AP","Meynell F","Gisondi P","Di Meglio P","Urmston D","Griffiths CEM","Galloway JB","Tsakok T","Weinman J","Warren RB","PsoProtect, CORE-UK study groups","Norton S","Waweru H","Vincent A","Lancelot C","Bachelez H","Jullien D"],"additional_accession":[]},"is_claimable":false,"name":"Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.","description":"<h4>Background</h4>Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments.<h4>Objectives</h4>We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation.<h4>Methods</h4>Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-04-04T03:06:26.122Z","creation":"2025-02-19T05:06:21.835Z"},"accession":"S-EPMC9214088","cross_references":{"pubmed":["33368145"],"doi":["10.1111/bjd.19755"]}}